Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Biphenotypic, Acute 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, T-Cell 2 Burkitt Lymphoma 2 Rhabdoid Tumor 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Prostatic Neoplasms 1 Prostate Cancer Metastatic 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pinealoma 1 Pancreatitis 1 Pancreatic Intraductal Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neuroblastoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Medulloblastoma 1 Lymphoma, B-Cell 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Fistula 1 Duodenal Neoplasms 1 Down Syndrome 1 Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Radiosurgery 3 Androgen Antagonists 3 pembrolizumab 1 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 cabazitaxel 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostate Cancer Metastatic × Hydrocortisone × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡